Therapeutic options in the management of acromegaly: focus on lanreotide Autogel^®

Abstract

Background

In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.

Objective

To delineate the role of lanreotide in the treatment of acromegaly.

Methods

Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.

Results

Treatment with lanreotide slow release and lanreotide Autogel^® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel^® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.

Keywords:

• acromegaly
• lanreotide
• somatostatin analog
• growth hormone
• pegvisomant

Disclosures

The authors have no conflict of interest and have received no payment in the preparation of this manuscript.